ecraprost profile

Ecraprost: a prodrug of prostaglandin E1; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6917049
CHEMBL ID	2104574
SCHEMBL ID	4974845
MeSH ID	M0286485

Synonyms (26)

Synonym
ecraprost (usan/inn)
136892-64-3
D02723
ecraprost
butyl 7-[(4r,5r)-2-butanoyloxy-4-hydroxy-5-[(e,3s)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate
ecraprost [usan:inn]
butyl (4r,5r)-2,4-dihydroxy-5-((1e,3s)-3-hydroxy-1-octenyl)-1-cyclopentene-1-heptanoate, 2-butyrate
lipo-pro-prostaglandin e1
lipo as-013
circulase
as 013
butyryl prostaglandin f1 butyl ester
as-013
prosta-8,13-dien-1-oic acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11 alpha, 13e,15s)-
prosta-8,13-dien-1-oic acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11alpha,13e,15s)-
unii-q2xm6vr8do
q2xm6vr8do ,
CHEMBL2104574
ecraprost [inn]
butyl (4r,5r)-2,4-dihydroxy-5-[(1e,3s)-3-hydroxy-1-octenyl]-1-cyclopentene-1-heptanoate, 2-butyrate
ecraprost [usan]
prosta-8,13-dien-1-oic acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11.alpha.,13e,15s)-
SCHEMBL4974845
Q27286929
butyl 7-((4r,5r)-2-(butyryloxy)-4-hydroxy-5-((s,e)-3-hydroxyoct-1-en-1-yl)cyclopent-1-en-1-yl)heptanoate
AKOS040746791

Research

Studies (4)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.56 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (40.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	3 (60.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
9-diazomethylanthracene 9-diazomethylanthracene: RN & N1 from 9th CI Form Index	1.99	1	0
alprostadil [no description available]	2.4	2	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent

Condition	Relationship Strength	Studies
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	2.93	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.99	1
Distorted Hearing [description not available]	1.99	1
Blood Clot [description not available]	1.99	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	1.99	1
Blood Pressure, High [description not available]	2	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2	1

ecraprost

Description